The Dana-Farber Bing Center for Waldenstrom's Macroglobulinemia Web site is intended to provide general information about the program, its care and research programs, and about Waldenstrom's Macroglobulinemia and related diseases. This site also provides links to health information that may be written by Dana-Farber staff or by outside providers, and access (links) to some external Web sites for your convenience. The Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible for the availability, accuracy, or content of these external sites, nor does it endorse them.

No Medical Advice Given
This site is not an attempt to practice medicine or provide specific medical advice, nor does the use of the site establish a doctor-patient relationship. For medical treatment or answers to personal questions, we strongly encourage you to consult with a qualified health care provider. For advice about your own care, please ask your doctor!

Restrictions on Use
You assume full responsibility for using the information on this site, and you understand and agree that the Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible or liable for any claim, loss, or damage resulting from its use. While we try to keep the information on the site as accurate as possible, we disclaim any warranty concerning its accuracy, timeliness, and completeness, and any other warranty, express or implied, including warranties of merchantability or fitness for a particular purpose. The Dana-Farber Waldenstrom's Macroglobulinemia Program also does not warrant that access to the site will be error- or virus-free.

Copyright Infringement
Material on the Dana-Farber Waldenstrom's Macroglobulinemia Program Web site is protected by copyright law. Unless otherwise stated, users may print or download information from this site for personal, non-commercial use only. Permission to reprint or otherwise reproduce any document in whole or in part is prohibited, unless prior written consent is obtained from the copyright owner.

Latest Bing Center News

29th Annual IWMF Educational Forum

29th Annual IWMF Educational Forum

Join us May 3-5, 2024, at the Hyatt Regency in Renton, Washington for the 2024 Ed Forum. Renton, Washington is a lively suburb of Seattle and nestled on the southeast shore of Lake Washington. The Hyatt Regency and Lake Washington provide a picturesque backdrop to support education and engagement for the WM community.

Read more..

A Cure in Sight for Waldenstrom's Macroglobulinemia

A Cure in Sight for Waldenstrom's Macroglobulinemia

Dr. Steven Treon explains how recent advances in understanding the genomics and biology of Waldenstrom's macroglobulinemia make him hopeful and optimistic about a cure.

Read more..

Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy

Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, institute physician, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses preliminary data from a phase 2 study (NCT05065554) of acalabrutinib (Calquence) plus rituximab (Rituxan) in patients with Waldenström’s Macroglobulinemia or IgM symptomatic anti-myelin associated glycoprotein (MAG)–mediated peripheral neuropathy.

Read more..

Dr Castillo on the Efficacy of Iopofosine I 131 in Waldenström Macroglobulinemia

Dr Castillo on the Efficacy of Iopofosine I 131 in Waldenström Macroglobulinemia

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, institute physician, Dana-Farber Cancer Institute, associate professor, medicine, Harvard Medical School, discusses the efficacy of treatment with iopofosine I 131 (previously CLR 131) in patients with Waldenström macroglobulinemia.

Read more..

Waldenstrom Macroglobulinemia: Who Gets What and When?

Waldenstrom Macroglobulinemia: Who Gets What and When?

As many as 50% of people at the time of their Waldenstrom macroglobulinemia (WM) diagnosis won’t need drug therapy for a number of years. We spoke with Shayna Sarosiek, MD, hematologist/oncologist from at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, to share what “supportive treatments” could help in the meantime.

Read more..

In Memoriam of Dr. Enrica Morra

In Memoriam of Dr. Enrica Morra

Dear Members of the Waldenstrom’s Macroglobulinemia Community: I wanted to share with you the sad news that our colleague and friend, Dr. Enrica Morra recently passed away. Dr. Morra was the Co-Chair of 6th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM) which was held in Venice, Italy (2010), and a recipient of the Jan Gosta Waldenstrom Award for Lifetime Contributions to Waldenstrom’s Macroglobulinemia at the 8th IWWM in London, UK (2014).

Read more..

ASH-2023 Posters Presented

ASH-2023 Posters Presented

The following posters were presented by the Bing Center at the ASH 2023 meeting, December 9-12, 2023 in San Diego. For more information about the ASH 2023 meeting, please visit https://www.hematology.org/meetings/annual-meeting.

Read more..

ASH 2023 - Bing Center Abstracts to be Presented

ASH 2023 - Bing Center Abstracts to be Presented

The following abstracts represent the research that will be presented by the Bing Center at the ASH 2023 meeting, December 9-12, 2023 in San Diego. For more information about the ASH 2023 meeting, please visit https://www.hematology.org/meetings/annual-meeting.

Read more..

Waldenstrom: Reaching the Relapsed Refractory Stage

Waldenstrom: Reaching the Relapsed Refractory Stage

Waldenstrom Macroglobulinemia (WM) is not curable, which means most patients will either reach the relapsed or refractory stage at some point in their journey. Patient Power spoke with Shayna Sarosiek, MD, hematologist/oncologist from at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, to share what reaching these stages mean for WM patients.

Read more..

Waldenstrom Macroglobulinemia: Who Gets What and When?

Waldenstrom Macroglobulinemia: Who Gets What and When?

As many as 50% of people at the time of their Waldenstrom macroglobulinemia (WM) diagnosis won’t need drug therapy for a number of years. We spoke with Shayna Sarosiek, MD, hematologist/oncologist from at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, to share what “supportive treatments” could help in the meantime.

Read more..